Table II.
bDLE affects IL-6, IL-8 and TNF-α production in K562 cells.
| Cytokine production, pg/ml | ||||
|---|---|---|---|---|
| Treatment | IL-1β | IL-6 | IL-8 | TNF-α |
| Untreated cells | 0.0 | 126.03 | 18.84 | 830.47 |
| bDLE 0.07 U/ml | 0.0 | 307.83 | 56.22 | 1384.69 |
| bDLE 0.14 U/ml | 0.0 | 342.26 | 54.4 | 1882.90 |
| bDLE 0.21 U/ml | 0.0 | 293.94 | 23.22 | 950.22 |
| bDLE 0.28 U/ml | 0.0 | 213.17 | 27.06 | 431.83 |
| bDLE 0.35 U/ml | 0.0 | 115.18 | 34.95 | 310.54 |
| PMA | 7.17 | 991.06 | 17915.32 | 2347.26 |
| DMSO | 0 | 4.29 | 2.96 | 37.96 |
K562 cells were treated with bDLE, PMA or DMSO, and following 96 h of incubation the supernatants were harvested and prepared according to the manufacturer's protocol (Cytometric Bead Array Human Inflammatory Cytokines kit; BD Biosciences). A total of 10,000 events were analyzed by flow cytometry. bDLE, bovine dialyzable leukocyte extract; IL, interleukin; TNF, tumor necrosis factor; PMA, phorbol myristate acetate; DMSO, dimethyl sulfoxide.